Xilio Therapeutics Analyst Ratings
Xilio Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/27/2023 | 148.14% | Morgan Stanley | $20 → $10 | Maintains | Overweight |
| 12/21/2022 | 73.7% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 11/10/2022 | 222.58% | Raymond James | $31 → $13 | Maintains | Outperform |
| 08/10/2022 | 396.28% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 793.3% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 669.23% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 694.04% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/27/2023 | 148.14% | 摩根士丹利 | 二十元 → 十美元 | 維護 | 超重 |
| 12/21/2022 | 73.7% | 查丹資本 | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
| 11/10/2022 | 222.58% | 雷蒙詹姆斯 | 三十一元 → 十三美元 | 維護 | 跑贏大市 |
| 2022 年 8 月 10 日 | 396.28% | 摩根士丹利 | 三二元 → 20 美元 | 維護 | 超重 |
| 2022 年 1 月 10 日 | 793.3% | HC 溫賴特 & 有限公司. | → 三十六美元 | 啟動覆蓋範圍 | → 購買 |
| 11/16/2021 | 669.23% | 雷蒙詹姆斯 | → 三十一美元 | 啟動覆蓋範圍 | → 跑贏大市 |
| 11/16/2021 | — | 科恩 & 有限公司. | 啟動覆蓋範圍 | → 跑贏大市 | |
| 11/16/2021 | 694.04% | 摩根士丹利 | → 三十二美元 | 啟動覆蓋範圍 | → 超重 |
What is the target price for Xilio Therapeutics (XLO)?
西里奧治療學（XLO）的目標價格是多少？
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on January 27, 2023. The analyst firm set a price target for $10.00 expecting XLO to rise to within 12 months (a possible 148.14% upside). 4 analyst firms have reported ratings in the last year.
摩根士丹利於 2023 年 1 月 27 日報導了西里奧治療（納斯達克代碼：XLO）的最新價格目標。該分析師公司設定了 10.00 美元的價格目標，預計 XLO 將在 12 個月內上升（可能上漲 148.14％）。4 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Xilio Therapeutics (XLO)?
西里歐藥物治療學（XLO）的最新分析師評級是什麼？
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
西里奧治療（NASDAQ：XLO）的最新分析師評級由摩根士丹利提供，西里奧治療學保持其超重評級。
When is the next analyst rating going to be posted or updated for Xilio Therapeutics (XLO)?
西里奧治療學（XLO）的下一個分析師評級何時會發布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.
分析師在進行了廣泛的研究後獲得了股票評級，其中包括通過公共財務報表，與 Xilio Therapotics 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。西里奧治療學的最後評級於 2023 年 1 月 27 日提交，因此您應該期望下一個評分將在 2024 年 1 月 27 日左右的某個時候提供。
Is the Analyst Rating Xilio Therapeutics (XLO) correct?
分析師評級西里奧治療學（XLO）是否正確？
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $20.00 to $10.00. The current price Xilio Therapeutics (XLO) is trading at is $4.03, which is out of the analyst's predicted range.
雖然評級是主觀的並且會發生變化，但最新的西里奧治療學（XLO）評級維持，目標價格為 20.00 美元至 10.00 美元。目前的價格西里奧治療學（XLO）的交易價格為 4.03 美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。